ArticleFrontiers in immunology2025

Evaluating the toxicity profile of combination immune checkpoint inhibitors: a disproportionality analysis of real-world adverse events from the FDA Adverse Event Reporting System for tremelimumab, durvalumab, ipilimumab, and nivolumab.

Zhuoyang Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.